z-logo
Premium
Disability, anxiety and depression in patients with medication‐overuse headache in primary care – the BIMOH study
Author(s) -
Kristoffersen E. S.,
Straand J.,
Russell M. B.,
Lundqvist C.
Publication year - 2016
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12850
Subject(s) - medicine , anxiety , depression (economics) , hospital anxiety and depression scale , population , randomized controlled trial , physical therapy , psychiatry , pediatrics , environmental health , economics , macroeconomics
Background and purpose Medication‐overuse headache ( MOH ) is common in the general population. Detoxification is the general treatment principle for MOH . The present paper is based on a study of a brief intervention ( BI ) for MOH in primary care. New data on headache disability and the Hospital Anxiety and Depression Scale ( HADS ) for MOH patients compared to population controls with and without chronic headache are presented and compared to previously published main outcome data. Methods This was a double‐blind pragmatic cluster randomized controlled trial carried out amongst 50 general practitioners in Norway. The BI was compared to business as usual ( BAU ) and population controls, and patients were followed up after 3 months. Primary outcomes were headache and medication days per month after 3 months. Headache disability and HADS were also measured as secondary outcomes. Results Sixty MOH patients and 40 population controls were included. BI was significantly better than BAU after 3 months regarding primary outcomes. Non‐intervention population controls did not change. The MOH patients had significantly higher headache disability and anxiety scores than the population controls. Conclusions Patients with MOH are a highly disabled group where anxiety and depression are important comorbidities. Detoxification of MOH by a BI in primary care is effective and has potential for saving resources for more treatment‐resistant cases in neurologist care.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here